

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities and neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever. Neither this announcement nor any copy hereof may be taken into or distributed in the United States of America (the “**United States**”).*

*The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Existing Convertible Bonds mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the Existing Convertible Bonds will be made in the United States.*



微創醫療科學有限公司\*

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 00853)

**PROPOSED REPURCHASE OF  
THE US\$700 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026**

Dealer Managers

J.P.Morgan



BofA SECURITIES 

References are made to the announcements of MicroPort Scientific Corporation (the “**Company**”) dated 11 June 2021 and 15 June 2021 in relation to the issue of the US\$700 million aggregate principal amount zero coupon convertible bonds due 2026 (of which US\$665 million remains outstanding) (Bond stock code: 40720, ISIN: XS2342920050) by the Company (the “**Existing Convertible Bonds**”).

Pursuant to Condition 8(f) (Purchase) of the terms and conditions of the Existing Convertible Bonds (the “**Conditions**”), the Company or any of its subsidiaries may at any time and from time to time purchase the Existing Convertible Bonds at any price in the open market or otherwise. The Company now proposes to repurchase the Existing Convertible Bonds pursuant to the Conditions.

On 5 December 2023, the Company entered into the dealer manager agreement (the “**Dealer Manager Agreement**”) in connection with the proposed repurchase of the Existing Convertible Bonds by the Company (the “**Repurchase**”) pursuant to which the Company has appointed J.P. Morgan Securities plc, China International Capital Corporation Hong Kong Securities Limited, Citigroup Global Markets Limited and Merrill Lynch (Asia Pacific) Limited as the dealer managers to, amongst others, assist the Company in collecting indications of interest from holders of the outstanding Existing Convertible Bonds who are willing to sell some or all of their Existing Convertible Bonds to the Company.

The Repurchase will not be conducted within or offered to the United States or to persons located or resident in the United States, or to a person acting on behalf of a beneficial owner of the Existing Convertible Bonds located or resident in the United States or acting for the account or benefit of any person located or resident in the United States.

**Completion of the Repurchase is subject to, among other things, the conditions set forth in the Dealer Manager Agreement, market conditions and investors’ demand. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company. Further announcement(s) in respect of the Repurchase will be made by the Company as and when appropriate.**

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr. Zhaohua Chang**  
*Chairman*

Shanghai, the PRC, 5 December 2023

*As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun, Dr. Qiyi Luo and Mr. Bo Peng; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *For identification purpose only.*